Revolution Medicines, Inc. (RVMD)

NASDAQ: RVMD · IEX Real-Time Price · USD
31.93
+0.21 (0.66%)
Mar 28, 2024, 1:56 PM EDT - Market open

Company Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.

The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial.

Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc.
Revolution Medicines logo
Country United States
Founded 2014
IPO Date Feb 13, 2020
Industry Biotechnology
Sector Healthcare
Employees 378
CEO Dr. Mark A. Goldsmith Ph.D.

Contact Details

Address:
700 Saginaw Dr
Redwood City, California 94063
United States
Phone 415-766-3638
Website revmed.com

Stock Details

Ticker Symbol RVMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001628171
CUSIP Number 76155X100
ISIN Number US76155X1000
Employer ID 47-2029180
SIC Code 2836

Key Executives

Name Position
Dr. Mark A. Goldsmith Ph.D. Chief Executive Officer, President and Chairman
Jack Anders Chief Financial Officer
Margaret A. Horn J.D. Chief Operating Officer
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. President of Research and Development
Xiaolin Wang Executive Vice President of Clinical Development
Dr. Martin D. Burke M.D., Ph.D. Co-Founder and Chairman of Scientific Advisory Board
Dr. Michael A. Fischbach Ph.D. Academic Co-Founder and Member of Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D. Academic Co-Founder and Member of Scientific Advisory Board
Walter Reiher Ph.D. Chief Information Officer
Jan Smith Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 27, 2024 144 Filing
Mar 15, 2024 144 Filing
Mar 15, 2024 144 Filing
Mar 15, 2024 144 Filing
Mar 15, 2024 144 Filing
Mar 15, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 4, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 26, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 26, 2024 10-K Annual Report